NCT05657834View on ClinicalTrials.gov

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

December 21, 2022

Study Completion Date

December 21, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

[14C]-TVB-2640

50 mg of TVB-2640 oral administration

Trial Locations (1)

68502

Celerion Inc., Lincoln

All Listed Sponsors

lead

Sagimet Biosciences Inc.

INDUSTRY